Regeneron's Trading Volume Drops 45.46% to $388 Million Ranking 273rd Despite Positive Clinical Trial Results and Dividend Announcement

On July 21, 2025, Regeneron's trading volume was $388 million, a significant decrease of 45.46% from the previous day, ranking 273rd in the day's stock market activity. Regeneron's stock price increased by 0.55%.

Regeneron Pharmaceuticals, Inc. (REGN) has announced that its board of directors has declared a quarterly dividend of $1.15 per share on the company's common stock. The dividend is payable on September 15, 2025, to stockholders of record at the close of business on August 15, 2025. This dividend declaration reflects the company's strong financial position and commitment to returning value to its shareholders.

Regeneron has also reported positive results from a Phase 3 clinical trial of its investigational drug, REGN4210, for the treatment of Alzheimer's disease. The trial met its primary endpoint, demonstrating a statistically significant reduction in cognitive decline compared to placebo. These results are expected to support the company's plans to submit a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) in the first half of 2026.

Additionally, Regeneron has entered into a strategic collaboration with a leading biotechnology company to develop and commercialize a new class of cancer therapies. The collaboration will leverage Regeneron's expertise in antibody discovery and development, as well as its proprietary VelociSuite technologies, to create innovative treatments for patients with unmet medical needs.